Abstract
In article number 2200236, Zhihong Zhang, Xiang Yu, and co-workers achieve the direct size conversion of erythrocyte-derived MVs (eMVs) via incubation with an ApoA-I mimetic peptide (R4F) capable of binding phospholipids. R4F peptide modification endows eMVs with SR-B1 receptor and lymph node targeting functions, providing an excellent drug delivery system for the targeted treatment of lymph node-associated diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
